Loy Bertrand
- SEC CIK
- 0001197452
In the past year, 5 open-market sale filings worth $36.2M and no purchases.
Current role at each company
- ITT Itt Inc.Directoras of Aug 4, 2026
- ENTG Entegris IncExecutive Chairas of Aug 4, 2026
- ASH Ashland Inc.Directoras of May 18, 2026
- HBIO Harvard Bioscience IncDirectoras of May 23, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $36.2M
- 5 filings
- Net
- −$36.2M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Loy Bertrand as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ENTG Entegris Inc
Executive Chair11 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 (view filing) | Apr 17 | 3 days | Loy BertrandExecutive Chair | SSale | −44.1K | $144.41 | −$6.37M | −16.2%227.5K after | 10b5-1 |
| Apr 16, 2026 (view filing) | Apr 14 | 2 days | Loy BertrandExecutive Chair | SSale | −17.4K | $140.22 | −$2.44M | −7.1%227.5K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24-25 | 2 days | Loy BertrandExecutive Chair | SSale | −109.8K | $138.25 | −$15.2M | −33.5%217.8K after | 7 lots10b5-1 |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Loy BertrandExecutive Chair | SSale | −65.3K | $119.61 | −$7.80M | −17.6%306.4K after | 6 lots10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Loy BertrandExecutive Chair | SSale | −57.6K | $76.88 | −$4.43M | −15.8%305.8K after | 3 lots10b5-1 |
| Jul 8, 2024 (view filing) | Jul 3 | 5 days | Loy BertrandPresident & CEO | SSale | −27.0K | $140.63 | −$3.80M | −9.3%263.1K after | 3 lots10b5-1 |
| Aug 13, 2021 (view filing) | Aug 11 | 2 days | Loy BertrandPresident & CEO | SSale | −23.7K | $116.66 | −$2.77M | −100.0%0 after | From original5 lots |
| Aug 11, 2021 (view filing) | Aug 9 | 2 days | Loy BertrandPresident & CEO | SSale | −9.81K | $121.47 | −$1.19M | −5.3%174.1K after | 2 lots |
| Aug 11, 2021 (view filing) | Aug 9-10 | 2 days | Loy BertrandPresident & CEO | SSale | −130.0K | $120.76 | −$15.7M | −84.6%23.7K after | 6 lots |
| Aug 6, 2021 (view filing) | Aug 4 | 2 days | Loy BertrandPresident & CEO | SSale | −17.0K | $125.42 | −$2.13M | −8.5%183.9K after | 2 lots |
HBIO Harvard Bioscience Inc
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 29, 2022 (view filing) | Aug 26 | 3 days | Loy BertrandDirector | PPurchase | +9.29K | $3.41 | +$31.7K | +2.4%399.7K after | |
| Aug 26, 2022 (view filing) | Aug 24-25 | 2 days | Loy BertrandDirector | PPurchase | +25.5K | $3.27 | +$83.4K | +7.0%390.4K after | 2 lots |
| Aug 24, 2022 (view filing) | Aug 22-23 | 2 days | Loy BertrandDirector | PPurchase | +13.9K | $3.21 | +$44.4K | +3.9%364.8K after | 2 lots |
| Aug 22, 2022 (view filing) | Aug 18-19 | 4 days | Loy BertrandDirector | PPurchase | +10.8K | $3.27 | +$35.2K | +3.2%351.0K after | 2 lots |